Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Marks J, Humphrey P, Wu K, Berry D, Bandarenko N, Kerns B, Iglehart J. Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. Annals Of Surgery 1994, 219: 332-341. PMID: 7909221, PMCID: PMC1243148, DOI: 10.1097/00000658-199404000-00002.Peer-Reviewed Original ResearchConceptsHER-2/neuEarly-stage breast cancerStage breast cancerHER-2/neu oncogeneBreast cancerPrognostic valueHER-2/neu proteinNeu oncogeneGenetic abnormalitiesDuke University Medical CenterFailure-free survivalProgesterone receptor contentCohort of patientsLimited prognostic valueIndependent prognostic valueShorter survival timeParaffin-embedded specimensUniversity Medical CenterHER-2/neu geneOverexpression of p53Common genetic abnormalityNodal statusRetrospective cohortLow estrogenTumor sizeOverexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors
Berchuck A, Kohler M, Hopkins M, Humphrey P, Robboy S, Rodriguez G, Soper J, Clarke-Pearson D, Bast R. Overexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors. Gynecologic Oncology 1994, 52: 232-236. PMID: 7508877, DOI: 10.1006/gyno.1994.1037.Peer-Reviewed Original ResearchConceptsEpithelial ovarian tumorsOverexpression of p53Borderline epithelial ovarian tumorsEpithelial ovarian cancerOvarian tumorsBorderline tumorsOvarian cancerEarly-stage borderline ovarian tumorsStage I/II casesBenign epithelial ovarian tumorsInvasive epithelial ovarian cancerBorderline ovarian tumorsBenign ovarian tumorsStage III casesAdvanced stage casesBenign tumorsMutant p53 proteinP53 tumor suppressor gene productIII casesStage casesTumorsII casesP53 proteinTumor suppressor gene productP53